×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Announces Webcast of Second-Quarter 2002 Financial Results

THOUSAND OAKS, Calif. July 16, 2002 -- Amgen (NASDAQ:AMGN) today announced that it will report second-quarter 2002 financial results on Wednesday, July 24, 2002, after the financial markets close. The announcement will be followed by a conference call at 2: 15 PM (PDT) with the investment community, featuring Kevin Sharer, Chairman, CEO and President and other members of Amgen's senior management.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call is expected to last approximately one hour.

This event can be accessed by going to Amgen's website, www.amgen.com, and clicking on Investor Center, then on Amgen Events. The event will be archived and available for replay for 72 hours after the conference call.

Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology.

# # #

Contact: Amgen, Thousand Oaks
David Kaye, 805/447-6692 (media)
Cary Rosansky, 805/447-4634 (investors)